ADOPTED REGULATION OF THE

STATE BOARD OF HEALTH

LCB File No. R051-97

Effective October 30, 1997

EXPLANATION – Matter in *italics* is new; matter in brackets **[ ]** is material to be omitted.

AUTHORITY: NRS 233B.050.

Section 1. Chapter 585 of NAC is hereby amended by adding thereto a new section to read as follows:

1. The board will consider an application for a license required pursuant to NAC 585.220 to manufacture, prepare or compound amygdalin (laetrile) or procaine hydrochloride with preservatives and stabilizers, and the written recommendation of the commissioner regarding the application, at a public hearing held:

(a) At the time and place of the next regularly scheduled meeting of the board;

(b) At the next meeting of the board that is scheduled in Reno or Las Vegas, whichever city is requested by the applicant; or

(c) As soon as the schedule of the board permits.

2. The board is not required to follow the written recommendation of the commissioner regarding the application.

3. At the public hearing, the applicant and the commissioner may address the board and answer any questions of the board regarding the application.

4. In addition to complying with the requirements set forth in NAC 585.220, the board will not grant a license to manufacture, prepare or compound amygdalin (laetrile) or procaine hydrochloride with preservatives and stabilizers unless the applicant has satisfied the commissioner that the applicant has complied with the requirements for the issuance of such a license that are adopted by the commissioner.

5. At the conclusion of the presentations by the applicant and the commissioner, the board will render a decision granting or denying the application. The board will notify the applicant in writing of its findings of fact, conclusions of law and decision regarding the application as soon as practicable after the date of the hearing.